The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation
Open accessAbstract
Long-term survival and outcome were determined for 80 patients with immunoglobulin light chain (AL) amyloidosis treated with high-dose melphalan and stem cell transplantation (HDM/SCT) more than 10 years ago. Seventeen (21%) patients died within the first year of treatment, of treatment-related complications (14%) or progressive disease (8%). Of the 63 surviving evaluable patients at one year, 32 (51%) achieved a complete hematologic response (CR). For all 80 patients, the median survival was 57 months (4.75 yrs). The median survival exceeds 10 years for patients achieving a CR after HDM/SCT, compared with 50 months for those not achieving a CR (P < .001). In conclusion, HDM/SCT leads to durable remissions and prolonged survival, particularly for those patients who achieve a hematologic CR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Cited by
Transthyretin (TTR) Cardiac Amyloidosis
Ruberg, F. L., & Berk, J. L. (2012) · Circulation · doi:10.1161/circulationaha.111.078915 · Cited by 708
Amyloidosis: Pathogenesis and New Therapeutic Options
Merlini, G., Seldin, D. C., & Gertz, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2271 · Cited by 509
Self-citationComenzo, R. L., Reece, D., Palladini, G., Seldin, D., Sanchorawala, V, Landau, H., Falk, R., Wells, K., Solomon, A., Wechalekar, A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.100 · Cited by 390
Self-citationMikhael, J. R., Schuster, S. R., Jimenez-Zepeda, V. H., Bello, N., Spong, J., Reeder, C. B., Stewart, A. K., Bergsagel, P. L., & Fonseca, R. (2012) · Blood · doi:10.1182/blood-2011-11-390930 · Cited by 375
Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
Kastritis, E., Wechalekar, A. D., Dimopoulos, M. A., Merlini, G., Hawkins, P. N., Perfetti, V., Gillmore, J. D., & Palladini, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8220 · Cited by 298
Metadata
- Authors
- Sanchorawala, V., Skinner, M., Quillen, K., Finn, K. T., Doros, G., & Seldin, D. C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2007-11-15
- Volume
- 110
- Issue
- 10
- Pages
- 3561-3563
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2158206316
- Cited by
- 166
- References
- 1
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. https://app.cochat.ai/papers/10.1182/blood-2007-07-099481
- The paper
- Sanchorawala, V., Skinner, M., Quillen, K., Finn, K. T., Doros, G., & Seldin, D. C. (2007). Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. https://doi.org/10.1182/blood-2007-07-099481
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.